Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?

American Journal of Reproductive Immunology

Volumn 76, Issue 1, 2016, Pages 8-28

  Mekinian, Arsène ^a   Cohen, Jonathan ^b   Alijotas Reig, Jaume ^c   Carbillon, Lionel ^d   Nicaise Roland, Pascale ^e   Kayem, Gilles ^f   Daraï, Emile ^b   Fain, Olivier ^a   Bornes, Marie ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HÔPITAL JEAN VERDIER   (France)

^e BICHAT HOSPITAL   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Immunomodulation; implantation failure; pregnancy; unexplained miscarriages

Indexed keywords

ACETYLSALICYLIC ACID; ALGESTONE; AUTOANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTRALIPID; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RO ANTIBODY; THYROID ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; ENDOMETRIUM BIOPSY; FEMALE; HUMAN; IMMUNOMODULATION; LIVE BIRTH; MEDLINE; META ANALYSIS; META ANALYSIS (TOPIC); NIDATION; NONHUMAN; PLACENTA DISORDER; PLACENTAL INFLAMMATORY LESION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT ABORTION; REGULATORY T LYMPHOCYTE; REVIEW; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW (TOPIC); TH1 TH2 BALANCE; TH17 CELL;

EID: 84990216267     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12493     Document Type: Review

References (165)

1. Alijotas-Reig J, Garrido-Gimenez C: Current concepts and new trends in the diagnosis and management of recurrent miscarriage. Obstet Gynecol Surv 2013; 68:445–466.
2. Garrido-Gimenez C, Alijotas-Reig J: Recurrent miscarriage: causes, evaluation and management. Postgrad Med J 2015; 91:151–162.
3. Jaslow CR, Kutteh WH: Effect of prior birth and miscarriage frequency on the prevalence of acquired and congenital uterine anomalies in women with recurrent miscarriage: a cross-sectional study. Fertil Steril 2013; 99:1916–1922 e1911.
4. Carp HJ: Recurrent miscarriage: genetic factors and assessment of the embryo. Isr Med Assoc J 2008; 10:229–231.
5. Franssen MT, Korevaar JC, van der Veen F, Leschot NJ, Bossuyt PM, Goddijn M: Reproductive outcome after chromosome analysis in couples with two or more miscarriages: index [corrected]-control study. BMJ 2006; 32:759–763.
6. Rai R, Regan L: Recurrent miscarriage. Lancet 2006; 368:601–611.
7. Coulam CB, Stephenson M, Stern JJ, Clark DA: Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Am J Reprod Immunol 1996; 35:352–359.
8. Stephenson MD, Awartani KA, Robinson WP: Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study. Hum Reprod 2002; 17:446–451.
9. Thornhill AR, de Die-Smulders CE, Geraedts JP, Harper JC, Harton GL, Lavery SA, Moutou C, Robinson MD, Schmutzler AG, Scriven PN, Sermon KD, Wilton L: ESHRE PGD Consortium ‘Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)’. Hum Reprod 2005; 20:35–48.
10. Penzias AS: Recurrent IVF failure: other factors. Fertil Steril 2012; 97:1033–1038.
11. de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S: Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 2014; 7:CD004734.
12. Clark DA: Should anti-TNF-alpha therapy be offered to patients with infertility and recurrent spontaneous abortion? Am J Reprod Immunol 2009; 61:107–112.
13. Clark DA: Anti-TNFalpha therapy in immune-mediated subfertility: state of the art. J Reprod Immunol 2010; 85:15–24.
14. Alijotas-Reig J, Llurba E, Gris JM: Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta 2014; 35:241–248.
15. Lim KJ, Odukoya OA, Ajjan RA, Li TC, Weetman AP, Cooke ID: The role of T-helper cytokines in human reproduction. Fertil Steril 2000; 73:136–142.
16. Clark DA, Chaouat G, Arck PC, Mittruecker HW, Levy GA: Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase]. J Immunol 1998; 160:545–549.
17. Kwak-Kim JY, Chung-Bang HS, Ng SC, Ntrivalas EI, Mangubat CP, Beaman KD, Beer AE, Gilman-Sachs A: Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum Reprod 2003; 18:767–773.
18. Makhseed M, Raghupathy R, Azizieh F, Omu A, Al-Shamali E, Ashkanani L: Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum Reprod 2001; 16:2219–2226.
19. Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R: Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 2000; 15:713–718.
20. Lee SK, Na BJ, Kim JY, Hur SE, Lee MA, Gilman-Sachs A, Kwak-Kim J: Determination of clinical cellular immune markers in women with recurrent pregnancy loss. Am J Reprod Immunol 2013; 70:398–411.
21. Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J: Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. Am J Reprod Immunol 2002; 48:77–86.
22. Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E: Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell Immunol 1999; 196:122–130.
23. Liang PY, Diao LH, Huang CY, Lian RC, Chen X, Li GG, Zhao J, Li YY, He XB, Zeng Y: The pro-inflammatory and anti-inflammatory cytokine profile in peripheral blood of women with recurrent implantation failure. Reprod Biomed Online 2015; 31:823–826.
24. Boomsma CM, Kavelaars A, Eijkemans MJ, Lentjes EG, Fauser BC, Heijnen CJ, Macklon NS: Endometrial secretion analysis identifies a cytokine profile predictive of pregnancy in IVF. Hum Reprod 2009; 24:1427–1435.
25. Sakaguchi S, Miyara M, Costantino CM, Hafler DA: FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490–500.
26. Calleja-Agius J, Jauniaux E, Pizzey AR, Muttukrishna S: Investigation of systemic inflammatory response in first trimester pregnancy failure. Hum Reprod 2012; 27:349–357.
27. Dimitriadis E, White CA, Jones RL, Salamonsen LA: Cytokines, chemokines and growth factors in endometrium related to implantation. Hum Reprod Update 2005; 11:613–630.
28. Guzeloglu-Kayisli O, Kayisli UA, Taylor HS: The role of growth factors and cytokines during implantation: endocrine and paracrine interactions. Semin Reprod Med 2009; 27:62–79.
29. Plaks V, Birnberg T, Berkutzki T, Sela S, BenYashar A, Kalchenko V, Mor G, Keshet E, Dekel N, Neeman M, Jung S: Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest 2008; 118:3954–3965.
30. Ledee N, Petitbarat M, Rahmati M, Dubanchet S, Chaouat G, Sandra O, Perrier-d'Hauterive S, Munaut C, Foidart JM: New pre-conception immune biomarkers for clinical practice: interleukin-18, interleukin-15 and TWEAK on the endometrial side, G-CSF on the follicular side. J Reprod Immunol 2011; 88:118–123.
31. Nakashima A, Ito M, Yoneda S, Shiozaki A, Hidaka T, Saito S: Circulating and decidual Th17 cell levels in healthy pregnancy. Am J Reprod Immunol 2010; 63:104–109.
32. Wang WJ, Hao CF, Yi L, Yin GJ, Bao SH, Qiu LH, Lin QD: Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients. J Reprod Immunol 2010; 84:164–170.
33. Lee SK, Kim JY, Hur SE, Kim CJ, Na BJ, Lee M, Gilman-Sachs A, Kwak-Kim J: An imbalance in interleukin-17-producing T and Foxp3(+) regulatory T cells in women with idiopathic recurrent pregnancy loss. Hum Reprod 2011; 26:2964–2971.
34. Aluvihare VR, Kallikourdis M, Betz AG: Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5:266–271.
35. Schumacher A, Zenclussen AC: Regulatory T cells: regulators of life. Am J Reprod Immunol 2014; 72:158–170.
36. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S: Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod 2004; 10:347–353.
37. Bao SH, Wang XP, De Lin Q, Wang WJ, Yin GJ, Qiu LH: Decidual CD4+CD25+CD127dim/- regulatory T cells in patients with unexplained recurrent spontaneous miscarriage. Eur J Obstet Gynecol Reprod Biol 2011; 155:94–98.
38. Kim DJ, Lee SK, Kim JY, Na BJ, Hur SE, Lee M, Kwak-Kim J: Intravenous immunoglobulin G modulates peripheral blood Th17 and Foxp3(+) regulatory T cells in pregnant women with recurrent pregnancy loss. Am J Reprod Immunol 2014; 71:441–450.
39. Lachapelle MH, Miron P, Hemmings R, Roy DC: Endometrial T, B, and NK cells in patients with recurrent spontaneous abortion. Altered profile and pregnancy outcome. J Immunol 1996; 156:4027–4034.
40. Tuckerman E, Mariee N, Prakash A, Li TC, Laird S: Uterine natural killer cells in peri-implantation endometrium from women with repeated implantation failure after IVF. J Reprod Immunol 2010; 87:60–66.
41. Tuckerman E, Laird SM, Prakash A, Li TC: Prognostic value of the measurement of uterine natural killer cells in the endometrium of women with recurrent miscarriage. Hum Reprod 2007; 22:2208–2213.
42. Michimata T, Ogasawara MS, Tsuda H, Suzumori K, Aoki K, Sakai M, Fujimura M, Nagata K, Nakamura M, Saito S: Distributions of endometrial NK cells, B cells, T cells, and Th2/Tc2 cells fail to predict pregnancy outcome following recurrent abortion. Am J Reprod Immunol 2002; 47:196–202.
43. Quenby S, Nik H, Innes B, Lash G, Turner M, Drury J, Bulmer J: Uterine natural killer cells and angiogenesis in recurrent reproductive failure. Hum Reprod 2009; 24:45–54.
44. Plaisier M, Dennert I, Rost E, Koolwijk P, van Hinsbergh VW, Helmerhorst FM: Decidual vascularization and the expression of angiogenic growth factors and proteases in first trimester spontaneous abortions. Hum Reprod 2009; 24:185–197.
45. Kwak JY, Beaman KD, Gilman-Sachs A, Ruiz JE, Schewitz D, Beer AE: Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Am J Reprod Immunol 1995; 34:93–99.
46. King K, Smith S, Chapman M, Sacks G: Detailed analysis of peripheral blood natural killer (NK) cells in women with recurrent miscarriage. Hum Reprod 2010; 25:52–58.
47. Karami N, Boroujerdnia MG, Nikbakht R, Khodadadi A: Enhancement of peripheral blood CD56(dim) cell and NK cell cytotoxicity in women with recurrent spontaneous abortion or in vitro fertilization failure. J Reprod Immunol 2012; 95:87–92.
48. Thum MY, Bhaskaran S, Abdalla HI, Ford B, Sumar N, Shehata H, Bansal AS: An increase in the absolute count of CD56dimCD16+CD69+ NK cells in the peripheral blood is associated with a poorer IVF treatment and pregnancy outcome. Hum Reprod 2004; 19:2395–2400.
49. Coulam CB, Roussev RG: Correlation of NK cell activation and inhibition markers with NK cytoxicity among women experiencing immunologic implantation failure after in vitro fertilization and embryo transfer. J Assist Reprod Genet 2003; 20:58–62.
50. Aoki K, Kajiura S, Matsumoto Y, Ogasawara M, Okada S, Yagami Y, Gleicher N: Preconceptional natural-killer-cell activity as a predictor of miscarriage. Lancet 1995; 345:1340–1342.
51. Fukui A, Kwak-Kim J, Ntrivalas E, Gilman-Sachs A, Lee SK, Beaman K: Intracellular cytokine expression of peripheral blood natural killer cell subsets in women with recurrent spontaneous abortions and implantation failures. Fertil Steril 2008; 89:157–165.
52. Yamada H, Shimada S, Morikawa M, Iwabuchi K, Kishi R, Onoe K, Minakami H: Divergence of natural killer cell receptor and related molecule in the decidua from sporadic miscarriage with normal chromosome karyotype. Mol Hum Reprod 2005; 11:451–457.
53. Quack KC, Vassiliadou N, Pudney J, Anderson DJ, Hill JA: Leukocyte activation in the decidua of chromosomally normal and abnormal fetuses from women with recurrent abortion. Hum Reprod 2001; 16:949–955.
54. Vissenberg R, van den Boogaard E, van Wely M, van der Post JA, Fliers E, Bisschop PH, Goddijn M: Treatment of thyroid disorders before conception and in early pregnancy: a systematic review. Hum Reprod Update 2012; 18:360–373.
55. Kim CH, Chae HD, Kang BM, Chang YS: Influence of antithyroid antibodies in euthyroid women on in vitro fertilization-embryo transfer outcome. Am J Reprod Immunol 1998; 40:2–8.
56. Velkeniers B, Van Meerhaeghe A, Poppe K, Unuane D, Tournaye H, Haentjens P: Levothyroxine treatment and pregnancy outcome in women with subclinical hypothyroidism undergoing assisted reproduction technologies: systematic review and meta-analysis of RCTs. Hum Reprod Update 2013; 19:251–258.
57. Meloni GF, Dessole S, Vargiu N, Tomasi PA, Musumeci S: The prevalence of coeliac disease in infertility. Hum Reprod 1999; 14:2759–2761.
58. Collin P, Vilska S, Heinonen PK, Hallstrom O, Pikkarainen P: Infertility and coeliac disease. Gut 1996; 39:382–384.
59. Kutteh WH: Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997; 35:151–171.
60. Di Nisio M, Rutjes AW, Ferrante N, Tiboni GM, Cuccurullo F, Porreca E: Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood 2011; 118:2670–2678.
61. Paulmyer-Lacroix O, Despierres L, Courbiere B, Bardin N: Antiphospholipid antibodies in women undergoing in vitro fertilization treatment: clinical value of IgA anti-beta2glycoprotein I antibodies determination. Biomed Res Int 2014; 314704.
62. Sauer R, Roussev R, Jeyendran RS, Coulam CB: Prevalence of antiphospholipid antibodies among women experiencing unexplained infertility and recurrent implantation failure. Fertil Steril 2010; 93:2441–2443.
63. Gris JC, Quere I, Sanmarco M, Boutiere B, Mercier E, Amiral J, Hubert AM, Ripart-Neveu S, Hoffet M, Tailland ML, Rousseau O, Monpeyroux F, Dauzat M, Sampol J, Daures JP, Berlan J, Mares P: Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study–NOHA. Thromb Haemost 2000; 84:228–236.
64. Gris JC, Perneger TV, Quere I, Mercier E, Fabbro-Peray P, Lavigne-Lissalde G, Hoffet M, Dechaud H, Boyer JC, Ripart-Neveu S, Tailland ML, Daures JP, Mares P, Dauzat M: Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 2003; 102:3504–3513.
65. Ulcova-Gallova Z, Krauz V, Novakova P, Milichovska L, Micanova Z, Bibkova K, Sucha R, Turek J, Balvin M, Rokyta Z: Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol 2005; 54:112–117.
66. Sanmarco M, Bardin N, Camoin L, Beziane A, Dignat-George F, Gamerre M, Porcu G: Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci 2007; 1108:457–465.
67. Velayuthaprabhu S, Matsubayashi H, Sugi T, Nakamura M, Ohnishi Y, Ogura T, Tomiyama T, Archunan G: A unique preliminary study on placental apoptosis in mice with passive immunization of anti-phosphatidylethanolamine antibodies and anti-factor XII antibodies. Am J Reprod Immunol 2011; 66:373–384.
68. Oliver-Minarro D, Sanchez-Ramon S, Rodriguez-Mahou M, Alvarez S, Fernandez-Cruz E: Isolated type 5 antimitochondrial autoantibodies are associated with a history of thrombocytopenia and fetal loss. Fertil Steril 2007; 87:976 e917–978 e917.
69. Yelnik CM, Dubucquoi S, Houfflin-Debarge V, Lambert M: Antiphosphatidylethanolamine antibody as a marker of antiphospholipid syndrome?. Presse Med 2015; 44:284–291.
70. Ota K, Dambaeva S, Han AR, Beaman K, Gilman-Sachs A, Kwak-Kim J: Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod 2013; 29:208–219.
71. De Carolis S, Salvi S, Botta A, Garofalo S, Garufi C, Ferrazzani S, De Carolis MP: The impact of primary Sjogren's syndrome on pregnancy outcome: our series and review of the literature. Autoimmun Rev 2013; 13:103–107.
72. Haga HJ, Gjesdal CG, Koksvik HS, Skomsvoll JF, Irgens LM, Ostensen M: Pregnancy outcome in patients with primary Sjogren's syndrome. a case-control study. J Rheumatol 2005; 32:1734–1736.
73. Priori R, Gattamelata A, Modesti M, Colafrancesco S, Frisenda S, Minniti A, Framarino-dei-Malatesta M, Maset M, Quartuccio L, De Vita S, Bartoloni E, Alunno A, Gerli R, Strigini F, Baldini C, Tani C, Mosca M, Bombardieri S, Valesini G: Outcome of pregnancy in Italian patients with primary Sjogren syndrome. J Rheumatol 2015; 40:1143–1147.
74. Mekinian A, Nicaise-Roland P, Chollet-Martin S, Fain O, Crestani B: Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren's syndrome in the absence of anti-SSA/SSB antibodies by ELISA. Rheumatology (Oxford) 2013; 52:2223–2228.
75. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, Friedman D, Llanos C, Piette JC, Buyon JP: Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76–82.
76. Katzman PJ: Chronic inflammatory lesions of the placenta. Semin Perinatol 2014; 39:20–26.
77. Marchaudon V, Devisme L, Petit S, Ansart-Franquet H, Vaast P, Subtil D: Chronic histiocytic intervillositis of unknown etiology: clinical features in a consecutive series of 69 cases. Placenta 2011; 32:140–145.
78. Mekinian A, Costedoat-Chalumeau N, Masseau A, Botta A, Chudzinski A, Theulin A, Emmanuelli V, Hachulla E, De Carolis S, Revaux A, Nicaise P, Cornelis F, Subtil D, Montestruc F, Bucourt M, Chollet-Martin S, Carbillon L, Fain O: Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. Autoimmunity 2015; 48:40–45.
79. Labarrere C, Althabe O: Chronic villitis of unknown aetiology in recurrent intrauterine fetal growth retardation. Placenta 1987; 8:167–173.
80. Hulthen VI, Petersson K, Kublickas M, Papadogiannakis N: Both acute and chronic placental inflammation are overrepresented in term stillbirths: a case-control study. Infect Dis Obstet Gynecol 2012; 2012:293867.
81. Kim CJ, Romero R, Kusanovic JP, Yoo W, Dong Z, Topping V, Gotsch F, Yoon BH, Chi JG, Kim JS: The frequency, clinical significance, and pathological features of chronic chorioamnionitis: a lesion associated with spontaneous preterm birth. Mod Pathol 2010; 23:1000–1011.
82. Jacques SM, Qureshi F: Chronic chorioamnionitis: a clinicopathologic and immunohistochemical study. Hum Pathol 1998; 29:1457–1461.
83. Romero R, Whitten A, Korzeniewski SJ, Than NG, Chaemsaithong P, Miranda J, Dong Z, Hassan SS, Chaiworapongsa T: Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection? Am J Reprod Immunol 2013; 70:285–298.
84. Quaranta M, Erez O, Mastrolia SA, Koifman A, Leron E, Eshkoli T, Mazor M, Holcberg G: The physiologic and therapeutic role of heparin in implantation and placentation. PeerJ 2015; 3:e691.
85. Rai R, Backos M, Baxter N, Chilcott I, Regan L: Recurrent miscarriage–an aspirin a day? Hum Reprod 2000; 15:2220–2223.
86. Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, Schenk M, Henes M, Bohlmann MK, Fischer T, Brosteanu O, Bauersachs R, Petroff D: Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med 2015; 162:601–609.
87. Pasquier E, de Saint Martin L, Bohec C, Chauleur C, Bretelle F, Marhic G, Le Gal G, Debarge V, Lecomte F, Denoual-Ziad C, Lejeune-Saada V, Douvier S, Heisert M, Mottier D: Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood 2015; 125:2200–2205.
88. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, Buller HR, van der Veen F, Middeldorp S: Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362:1586–1596.
89. Potdar N, Gelbaya TA, Konje JC, Nardo LG: Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis. Hum Reprod Update 2013; 19:674–684.
90. Quenby S, Kalumbi C, Bates M, Farquharson R, Vince G: Prednisolone reduces preconceptual endometrial natural killer cells in women with recurrent miscarriage. Fertil Steril 2005; 84:980–984.
91. Lash GE, Innes BA, Drury JA, Robson SC, Quenby S, Bulmer JN: Localization of angiogenic growth factors and their receptors in the human endometrium throughout the menstrual cycle and in recurrent miscarriage. Hum Reprod 2011; 27:183–195.
92. Akhter A, Faridi RM, Das V, Pandey A, Naik S, Agrawal S: In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. Tissue Antigens 2012; 80:126–135.
93. Alijotas-Reig J: Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 2012; 22:6–17.
94. Gomaa MF, Elkholy AG, El-Said MM, Abdel-Salam NE: Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet 2014; 290:757–762.
95. Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey AA, Mosbah A: Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008; 278:33–38.
96. Tempfer CB, Kurz C, Bentz EK, Unfried G, Walch K, Czizek U, Huber JC: A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. Fertil Steril 2006; 86:145–148.
97. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, Farewell V, Farine D, Spitzer K, Fielding L, Soloninka CA, Yeung M: Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337:148–153.
98. Tang AW, Alfirevic Z, Turner MA, Drury JA, Small R, Quenby S: A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod 2013; 28:1743–1752.
99. Boomsma CM, Keay SD, Macklon NS: Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database Syst Rev 2012; 6:CD005996.
100. Nyborg KM, Kolte AM, Larsen EC, Christiansen OB: Immunomodulatory treatment with intravenous immunoglobulin and prednisone in patients with recurrent miscarriage and implantation failure after in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2014; 102:1650–1655 e1651.
101. Krigstein M, Sacks G: Prednisolone for repeated implantation failure associated with high natural killer cell levels. J Obstet Gynaecol 2012; 32:518–519.
102. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A: Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18:93–101.
103. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G: Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385–392.
104. Nelson-Piercy C, Fayers P, de Swiet M: Randomised, double-blind, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum. BJOG 2001; 108:9–15.
105. Carmichael SL, Shaw GM: Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999; 86:242–244.
106. Druckmann R, Druckmann MA: Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol 2005; 97:389–396.
107. Choi BC, Polgar K, Xiao L, Hil JA: Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 2000; 15(Suppl. 1):46–59.
108. Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J: Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol 2009; 80:91–99.
109. El-Zibdeh MY: Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005; 97:431–434.
110. Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S: Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014; 102(1357–1363):e1353.
111. Carp H: A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015; 1:1–9.
112. Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Bender Atik R, Bloemenkamp KW, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R: A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med 2015; 373:2141–2148.
113. Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ: Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005; 159:957–962.
114. Chaouat G, Menu E, Clark DA, Dy M, Minkowski M, Wegmann TG: Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy. J Reprod Fertil 1990; 89:447–458.
115. Heinz HP, Loos M: Activation of the first component of complement, C1: comparison of the effect of sixteen different enzymes on serum C1. Immunobiology 1983; 165:175–185.
116. Winger EE, Reed JL, Ashoush S, El-Toukhy T, Ahuja S, Taranissi M: Degree of TNF-alpha/IL-10 cytokine elevation correlates with IVF success rates in women undergoing treatment with Adalimumab (Humira) and IVIG. Am J Reprod Immunol 2009; 65:610–618.
117. Winger EE, Reed JL, Ashoush S, El-Toukhy T, Taranissi M: Die-off ratio correlates with increased TNF-alpha:IL-10 ratio and decreased IVF success rates correctable with humira. Am J Reprod Immunol 2012; 68:428–437.
118. Winger EE, Reed JL: Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008; 60:8–16.
119. Rychly DJ, DiPiro JT: Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005; 25:1181–1192.
120. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL: Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70:823–826.
121. Khan N, Asim H, Lichtenstein GR: Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf 2014; 13:1699–1708.
122. Marchioni RM, Lichtenstein GR: Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 2013; 19:2591–2602.
123. Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu DM, Meister R, Schaefer C: Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015; 80:727–739.
124. Robertson SA, Roberts CT, Farr KL, Dunn AR, Seamark RF: Fertility impairment in granulocyte-macrophage colony-stimulating factor-deficient mice. Biol Reprod 1999; 60:251–261.
125. Perricone R, De Carolis C, Giacomelli R, Guarino MD, De Sanctis G, Fontana L: GM-CSF and pregnancy: evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment. Am J Reprod Immunol 2003; 50:232–237.
126. Saito S, Fukunaga R, Ichijo M, Nagata S: Expression of granulocyte colony-stimulating factor and its receptor at the fetomaternal interface in murine and human pregnancy. Growth Factors 1994; 10:135–143.
127. Litwin S, Lagadari M, Barrientos G, Roux ME, Margni R, Miranda S: Comparative immunohistochemical study of M-CSF and G-CSF in feto-maternal interface in a multiparity mouse model. Am J Reprod Immunol 2005; 54:311–320.
128. Ledee N, Lombroso R, Lombardelli L, Selva J, Dubanchet S, Chaouat G, Frankenne F, Foidart JM, Maggi E, Romagnani S, Ville Y, Piccinni MP: Cytokines and chemokines in follicular fluids and potential of the corresponding embryo: the role of granulocyte colony-stimulating factor. Hum Reprod 2008; 23:2001–2009.
129. Scarpellini F, Sbracia M: Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. Hum Reprod 2009; 24:2703–2708.
130. Wurfel W, Santjohanser C, Hirv K, Buhl M, Meri O, Laubert I, von HI, Fiedler K, Krusmann J, Krusmann G: High pregnancy rates with administration of granulocyte colony-stimulating factor in ART-patients with repetitive implantation failure and lacking killer-cell immunglobulin-like receptors. Hum Reprod 2010; 25:2151–2152 author reply 2152.
131. Santjohanser C, Knieper C, Franz C, Hirv K, Meri O, Schleyer M, Wurfel W, Toth B: Granulocyte-colony stimulating factor as treatment option in patients with recurrent miscarriage. Arch Immunol Ther Exp Warsz 2013; 61:159–164.
132. Barad DH, Yu Y, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee HJ, Gleicher N: A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial thickness and clinical pregnancy rates. Fertil Steril 2014; 101:710–715.
133. Boxer LA, Bolyard AA, Kelley ML, Marrero TM, Phan L, Bond JM, Newburger PE, Dale DC: Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. Obstet Gynecol 2015; 125:197–203.
134. Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Freedman MH, Kannourakis G, Kinsey SE, Davis R, Scarlata D, Schwinzer B, Zeidler C, Welte K: Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72:82–93.
135. Mekinian A, Costedoat-Chalumeau N, Masseau A, Tincani A, De Caroli S, Alijotas-Reig J, Ruffatti A, Ambrozic A, Botta A, Le Guern V, Fritsch-Stork R, Nicaise-Roland P, Carbonne B, Carbillon L, Fain O: Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? Autoimmun Rev 2015; 14:23–29.
136. Marchetti T, Ruffatti A, Wuillemin C, de Moerloose P, Cohen M: Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost 2014; 12:910–920.
137. Wu XX, Guller S, Rand JH: Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol 2011; 205(576):e577–514.
138. Mekinian A, Lazzaroni MG, Kuzenko A, Alijotas-Reig J, Ruffatti A, Levy P, Canti V, Bremme K, Bezanahary H, Bertero T, Dhote R, Maurier F, Andreoli L, Benbara A, Tigazin A, Carbillon L, Nicaise-Roland P, Tincani A, Fain O: The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmun Rev 2015; 14:498–502.
139. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20–28.
140. Osadchy A, Ratnapalan T, Koren G: Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 2011; 38:2504–2508.
141. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, Frassi M, Biasini C, Zatti S, Chirico G: Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005; 25:86–89.
142. Yamada H, Morikawa M, Furuta I, Kato EH, Shimada S, Iwabuchi K, Minakami H: Intravenous immunoglobulin treatment in women with recurrent abortions: increased cytokine levels and reduced Th1/Th2 lymphocyte ratio in peripheral blood. Am J Reprod Immunol 2003; 49:84–89.
143. Graphou O, Chioti A, Pantazi A, Tsukoura C, Kontopoulou V, Guorgiadou E, Balafoutas C, Koussoulakos S, Margaritis LH, Varla-Leftherioti M: Effect of intravenous immunoglobulin treatment on the Th1/Th2 balance in women with recurrent spontaneous abortions. Am J Reprod Immunol 2003; 49:21–29.
144. Moraru M, Carbone J, Alecsandru D, Castillo-Rama M, Garcia-Segovia A, Gil J, Alonso B, Aguaron A, Ramos-Medina R, Martinez de Maria J, Oliver-Minarro D, Rodriguez-Mahou M, Ortega V, Caballero P, Melia E, Vidal J, Cianchetta-Sivori M, Esteban C, Vargas-Henny L, Dale J, Ortiz-Quintana L, Fernandez-Cruz E, Sanchez-Ramon S: Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56(+) cells. Am J Reprod Immunol 2012; 68:75–84.
145. Coulam CB, Acacio B: Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol 2012; 67:296–304.
146. Christiansen OB, Larsen EC, Egerup P, Lunoee L, Egestad L, Nielsen HS: Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomized, double-blind, placebo-controlled trial. BJOG 2015; 122:500–508.
147. Stephenson MD, Kutteh WH, Purkiss S, Librach C, Schultz P, Houlihan E, Liao C: Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod 2010; 25:2203–2209.
148. Clark DA: Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: methodological problems. Hum Reprod 2011; 26:2586–2587; author reply 2587–2589.
149. van den Heuvel MJ, Peralta CG, Hatta K, Han VK, Clark DA: Decline in number of elevated blood CD3(+) CD56(+) NKT cells in response to intravenous immunoglobulin treatment correlates with successful pregnancy. Am J Reprod Immunol 2007; 58:447–459.
150. Coulam CB, Krysa LW, Bustillo M: Intravenous immunoglobulin for in-vitro fertilization failure. Hum Reprod 1994; 9:2265–2269.
151. Shreeve N, Sadek K: Intralipid therapy for recurrent implantation failure: new hope or false dawn? J Reprod Immunol 2012; 93:38–40.
152. Clark DA: Intralipid as treatment for recurrent unexplained abortion? Am J Reprod Immunol 1994; 32:290–293.
153. Roussev RG, Acacio B, Ng SC, Coulam CB: Duration of intralipid's suppressive effect on NK cell's functional activity. Am J Reprod Immunol 2006; 60:258–263.
154. Roussev RG, Ng SC, Coulam CB: Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol 2007; 57:262–269.
155. Mayer K, Meyer S, Reinholz-Muhly M, Maus U, Merfels M, Lohmeyer J, Grimminger F, Seeger W: Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 2003; 171:4837–4843.
156. Nastri CO, Lensen SF, Gibreel A, Raine-Fenning N, Ferriani RA, Bhattacharya S, Martins WP: Endometrial injury in women undergoing assisted reproductive techniques. Cochrane Database Syst Rev 2015; 3:CD009517.
157. Coughlan C, Yuan X, Demirol A, Ledger W, Li TC: Factors affecting the outcome of “endometrial scratch” in women with recurrent implantation failure. J Reprod Med 2014; 59:39–43.
158. El-Khayat W, Elsadek M, Saber W: Comparing the effect of office hysteroscopy with endometrial scratch versus office hysteroscopy on intrauterine insemination outcome: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2015; 194:96–100.
159. Maged AM, Al-Inany H, Salama K, Souidan II M, Ragab HM, Elnassery N: Endometrial scratch injury induces higher pregnancy rate for women with unexplained infertility undergoing iui with ovarian stimulation: a randomized controlled trial. Reprod Sci 2015; 23:239–243.
160. Potdar N, Gelbaya T, Nardo LG: Endometrial injury to overcome recurrent embryo implantation failure: a systematic review and meta-analysis. Reprod Biomed Online 2012; 25:561–571.
161. Wadhwa L, Pritam A, Gupta T, Gupta S, Arora S, Chandoke R: Effect of endometrial biopsy on intrauterine insemination outcome in controlled ovarian stimulation cycle. J Hum Reprod Sci 2015; 8:151–158.
162. Clark CA, Spitzer KA, Laskin CA, Crowther MR, Ginsberg JS: Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss. Obstet Gynecol 2010; 116:997–998; author reply 998.
163. Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H: A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86:362–366.
164. Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KW, Kaaja RJ: Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011; 105:295–301.
165. Giancotti A, La Torre R, Spagnuolo A, D'Ambrosio V, Cerekja A, Piazze J, Chistolini A: Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. J Matern Fetal Neonatal Med 2012; 25:1191–1194.